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ABSTRACT
Inflammatory Myofibroblastic Tumor (IMT) is a rare pathologic entity that was first described in 1973. This lesion is most 
commonly found in the lungs, but other organs’ involvement has also been reported. Intracranial location of Inflammatory 
Myofibroblastic Tumor is rare, and the first case was reported in 1980. An intriguing fact about the intracranial IMT 
is its resemblance with meningioma on clinical presentation and neuroimaging. We came across a case of intracranial 
Inflammatory Myofibroblastic Tumor (IIMT) in a 27-year-old male who presented with recurrent episodes of seizures 
and was diagnosed as meningioma on neuroimaging. The lesion did not subside with medical management and kept 
on progressing in size. The patient had to undergo surgery, and diagnosis of Inflammatory Myofibroblastic Tumor was 
ascertained on histopathology. This ‘surprise’ diagnosis prompted us to review the literature on all cases of IIMTs reported 
to date to better understand the entity and its implications. In this review article, we present our observations regarding 
various studied parameters, including patient profile, clinical presentation, site of involvement, focality of the lesion, 
special associations, and lines of management of the 49 published cases of IIMTs. 
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INTRODUCTION
Inflammatory Myofibroblastic Tumor (IMT) 
is a rare enigmatic pathologic entity with poorly 
understood pathogenic mechanisms and progression. It 
is characterized by benign proliferation of inflammatory 
cells and is known by multiple synonyms such as (i) 
plasma cell granuloma, (ii) inflammatory pseudotumor, 
and (iii) cellular inflammatory pseudotumor. This entity 
was first described by Bahadori and Liebow in 1973,1 
and has been commonly reported in the lungs and the 
upper respiratory tract.
The intracranial location of this lesion is rare and 
was first reported by S G West et al.,2 in 1980.
Though in most of the cases, the lesions are unifocal, 
multifocal involvement of intracranial and extracranial 
sites has also been reported in some studies.3,4
The common presenting complaints of the IIMT 
are headache, seizures, ataxia, and visual disturbances. 
Cranial magnetic resonance imaging (MRI) shows 
enhancing lesions commonly associated with dural 
attachment, which closely mimics neuroimaging 
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findings of a meningioma. Histologically this lesion 
is characterized by proliferation of polyclonal plasma 
cells ascertained with kappa and lambda light chain, 
on immunohistochemistry.
Some studies have shown associations of IIMTs 
with polyclonal gammopathy, and one study has 
also reported an association with Epstein Barr Virus 
infection.5,6
We came across a case of IIMT is a 27-year-old 
previously healthy male who presented with episodes 
of generalized tonic-clonic seizures.
This case prompted us to research the literature on 
IIMTs to evaluate various parameters as patient profile, 
clinical presentation, site of involvement, focality of the 
lesion, special associations, and lines of management 
of IIMTs.
CASE REPORT
A 27-year-old previously healthy male presented 
with episodes of generalized tonic-clonic seizures. 
There was no history of headache, visual disturbances, 
ataxia, or paresis. The results of routine laboratory 
investigations, including complete blood count, blood 
biochemistry, urinalysis, and electrocardiogram were 
within normal limits. Chest X-ray and abdominal 
ultrasound were normal. The cranial MRI revealed 
an intensely enhancing extra-axial dural-based lesion 
measuring 4.6 x 2.8 x1.1 cm in the left frontoparietal 
area with mild associated perilesional edema and no 
significant mass effect, suggestive of meningioma 
(Figures 1A, and 1B).
The patient was continued on anti-epileptic 
medications with regular follow-ups. Surgical 
management was delayed in view of the small size of 
the lesion. While on medical management, the patient 
kept suffering recurrent episodes of generalized tonic-
clonic seizures.
Brain MRI was repeated after 5 months of the initial 
neuroimaging, which revealed increased dimensions 
of the lesion - 5.2 x 3.0 x 1.1 cm (Figures 1A, and 1B).
The patient then underwent elective surgery, and 
the surgical specimen of the excised space-occupying 
lesion was analyzed. The external surface of the 
specimen was smooth and firm. The cut surface was 
homogenous and yellowish-white in appearance. 
No areas of hemorrhage or necrosis were identified 
on the gross examination. The sample was fixed in 
10% formalin, embedded in paraffin, and stained 
with Hematoxylin &Eosin (H&E), Periodic Acid Schiff 
Figure 1. Brain MRI T1 weighted images post-contrast, A – axial plane, and B – sagittal plane, showing fat-saturated 
and avidly enhancing oval-shaped extra-axial lesion along the left frontoparietal convexity measuring 52mm in the 
longest dimension. The lesion shows a dural tail characteristic of meningioma.
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(PAS), Gram and Ziehl-Neelsen (ZN) Stains. Microscopic 
findings revealed a lesion composed of fibro-
collagenous stroma with interspersed endothelium 
lined blood vessels. Dense aggregates of inflammatory 
cells comprising predominantly of plasma cells along 
with lymphocytes were noted in the perivascular areas 
within the stroma (Figure 2).
Interspersed histiocytes with round vesicular 
nuclei and foamy cytoplasm were also noted. Normal 
brain parenchyma was noted at the periphery.
No meningothelial cells or psammoma bodies 
were seen. No atypia, mitosis, or necrosis was noted. 
PAS and ZN stains were negative for microorganisms. 
Histomorphological features favored the diagnosis 
of Intracranial Inflammatory Myofibroblastic Tumor. 
Immunohistochemical tests were done to confirm 
the diagnosis and to rule out monoclonal plasma cell 
proliferation. Immunohistochemistry was performed 
on deparaffinized sections of each case with CD138 
(Dako), Vimentin (Dako), SMA(Dako), S-100 (Dako), 
CD68(Dako), Anti Kappa (Biogenex), Anti Lambda 
polyclonal sera (Biogenex) using avidin biotin peroxidase 
complex. Plasma cells were positive for CD138 
and showed equal presence of kappa and lambda 
positivity. No evidence of clonal plasma cells was noted. 
Vimentin was diffusely positive in the stroma, SMA 
was positive in blood vessels. Histiocytes were positive 
for S100 and CD68. The diagnosis was confirmed 
as Intracranial Inflammatory Myofibroblastic Tumor. 
Additional serological tests were done to rule out 
Epstein Barr Virus (EBV) as infective etiology. EBV IgM 
ELISA was <10U/ML (<20U/ML: negative). EBV IgM to 
Nuclear Antigen was 2.64u/ml (<8: negative). EBV IgG 
ELISA was 0.42(<1.00 Negative). This case prompted 
us to review the literature on cases of Intracranial 
Inflammatory myofibroblastic tumor.
In our pre-specified protocol, the keywords 
“intracranial inflammatory myofibroblastic tumor, 
intracranial plasma cell granuloma, inflammatory 
pseudotumor and cellular inflammatory pseudotumor” 
were used to gather the target papers for a systematic 
review of the literature. The databases Google Scholar, 
Research Gate, and Pub Med were used to search 
the articles published until October 2020. All types of 
articles, including case reports, case series, pictorial 
assays with titles that included the aforementioned 
keywords, were studied.
All articles were evaluated for variables, including 
the year of publication, the number of studies 
published, and the number of cases reported in these 
studies.
Other parameters evaluated were clinical profile 
including age and gender, the chief presenting 
complaint, site of the lesion, focality of the lesion, 
association of the lesion with the dura, special 
features or findings associated with the intracranial 
Inflammatory Myofibroblastic Tumor, and the 
management approach.
RESULTS
After the review of literature, data on the published 
cases of intracranial inflammatory myofibroblastic 
tumors was compiled in chronological order (decade 
wise). (Table 1)
Out of the retrieved 42 articles on intracranial 
Inflammatory Myofibroblastic Tumors, 21 articles 
(the maximum) were published in 2001-2010, while 
6 of them (the least number) were published in the 
decade 1980-1990. The total number of cases reported 
in the 42 articles was 56. Out of these 56 cases, the 
variables studied could not be accessed in 07 of the 
cases; hence data of the remaining 49 cases was 
recorded and analyzed.
Figure 2. Histopathological examination with 
dense aggregates of inflammatory cells comprising 
predominantly of plasma cells (H&E, 40x).
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Presentation Site DA Associations Treatment
1 2 M 17 Headache L Posterior Fossa + PG CSE
2 7 F 16 Headache R Frontal lobe + - PSE, steroids, RT
3 8 M 16 Headache R Fronto-parietal lobe + - CSE
4 9 F 36 Hemiparesis Fourth ventricle - - CSE
5 10 F 29 Seizure R superior temporal gyrus + Necrosis CSE
6 5 M 60 Seizure R temporal lobe + PG CSE
7 11 M 11 Headache Frontal lobe NA - CSE
8
12
M 40 Headache R cavernous sinus - - PSE, steroids
9 M 30 Blindness L cavernous sinus - - PSE, Steroids
10 F 11 Headache Vermis cerebelli - - CSE
11 M 56 Diabetes Insipidus, Headache Pituitary stalk - - CSE
12 13 F 60 Seizure R middle cranial fossa + - CSE
13 6 M 70 Headache, Seizure, Subcutaneous mass R temporal lobe +












15 15 F 18 Headache R temporal lobe - - CSE
16 16 F 11 Seizure R frontal lobe + - CSE
17 17 F 34
L Ptosis, Transient 
oculomotor nerve 
palsy
Pituitary Stalk + - CSE
18 18 F 35 Seizure L parietal lobe NA - CSE




NA - PSE, steroids, ATT
20 19 M 13 Seizure R frontal lobe, lung NA
Involvement of lung 
followed by brain 4 years 
later
CSE
21 20 F 44 Headache R tentorium, Falx + - PSE, steroids, RT
22
21
F 6 Headache, tinnitus Cerebellopontine angle NA - PSE, RT
23 M 41 Seizure R occipital lobe NA - Systemic chemotherapy
24 F 33 Hearing loss Meninges + - PSE, RT
25 22 M 13 Seizure R frontal lobe NA - CSE
26 23 M 70 Visual disturbance Frontal lobe, third ventricle, Cranial base NA osteal erosion Steroids, RT
27 24 F 22 Seizure Temporo basal + - PSE, Steroid
28 22 F 14 Headache, R acute otitis media
Cavernous sinus, R 
middle cranial fossa, 
Infratemporal fossa
NA Raised IgM Steroids, RT, 6MP, MTX
29 25 F 18 Seizure L frontoparietal region + Extensive ossification PSE
30 26 M 63 L hemiparesis R frontal NA
Multiloculated cystic 
morphology, + Colon 
cancer
PSE, RT
CSE= complete surgical Excision; DA= Dural attachment, L= Left; NA=Non-available; 6MP=6 mercaptopurine, MTX= 
methotrexate, PSE: Partial surgical excision; PG= polyclonal gammopathy, R= Right; RIX= Rituximab; RT= radiotherapy
Phogat D, Datta SGS, Bajpai M, Tara S, Ganti SK




Presentation Site DA Associations Treatment
31 27 M 51 Headache Para sagittal + Relapsing perichondritis PSE, RT
32 28 F 58 Headache L frontotemporal lobe + - PSE, Steroid
33 29 F 44 Visual disturbance R Tentorium + - PSE, Steroids, RT
34
30
F 60 Blurred vision Posterior fossa + Ig G4 -, ALK - CSE, RT
35 F 52 R quadrantanopia R ventricle + Ig G4 +, ALK - CSE
36 M 45 hemiparesis Frontal lobe + Ig G4 +, ALK - CSE, Steroids
37 F 26 Headache Fronto temporal - Ig G4 +, ALK - CSE,Steroids
38 31 F 47 Seizures L parietal lobe - - CSE
39 32 M 59 Impaired vision Intrasellar, Trans-sphenoidal + - CSE, RT







F 47 1.Seizures L parietal lobe NA - CSE, steroids
42 M 56 L temporal headaches L basal ganglia NA - CSE, steroids




44 36 F 55 Headache, hearing loss L temporal lobe NA






M 52 Headache, blurred vision Clivus NA - CSE
46 F 55 Otalgia L ear with discharge
L nasopharynx and 
carotid space with 
osteolytic destruction
NA IgG4 + .RT
47 4 M 49 Gait ataxia Multiple, Bifrontal, temporal + - CSE
48 38 F 72 Headache L cerebellar hemisphere - - CSE
49 39 F 62 Seizures R Parietal lobe + - CSE
CSE= complete surgical Excision; DA= Dural attachment, L= Left; NA=Non-available; 6MP=6 mercaptopurine, MTX= 
methotrexate, PSE: Partial surgical excision; PG= polyclonal gammopathy, R= Right; RIX= Rituximab; RT= radiotherapy
It was observed that the cases were distributed 
over a wide range of ages ranging from 11 to 72 years. 
The average age of presentation was 29 years in the 
decade of 1980-1990 and 57 years in the decade of 
2010-2020. Out of the 49 studied cases, 22 were 
males, and 27 were females (male to female ratio of 
0.8:1). Headache was the most common presenting 
complaint seen in 18 (36%) cases, followed by seizures 
in 14 (28%) cases and visual disturbances in 8 (16%) 
cases. Other symptoms included hemiparesis, gait 
abnormalities, cranial nerve palsies, and hearing loss.
Concerning the lesion sites, the most common 
location was found to be the frontal lobe in 9 cases 
(18%), followed by the temporal lobe in 6 (12%) cases, 
the parietal lobe in 4(8%) cases, followed by 3 cases 
(6%) in the cavernous sinus and 2 (4%) cases in the 
cerebellopontine angle, and 02 (4%) cases showed 
multifocal intracranial involvement.
The dural attachment was noted in 22 (45%) 
cases and was absent in 11 (20%) cases, while it 
was not mentioned in the remaining. The condition 
was managed by complete surgical excision in 
21 (43%) cases, subtotal surgical excision followed by 
steroid therapy in 16 (32%) cases, and radiotherapy 
in 11(22%) cases.
DISCUSSION
Intracranial IMT (IIMT) is a rare clinical entity with 
42 published reports since the first reported case in 
Table 1. Continued...
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the year 1980. An interesting fact about IIMT is the 
striking resemblance with meningioma, concerning 
the clinical and neuroimaging profiles. This fact, 
along with the rarity of this entity, in the intracranial 
location, leads to the lack of clinical suspicion and 
a misdiagnosis. A study by Bradsma et al.21 showed 
how the two cases of IIMT were misdiagnosed as non-
Hodgkin Lymphoma and Tuberculosis.
Although benign, the lesion maintains a progressive 
growth and expands in size. While most cases recover 
after complete surgical excision, others may require 
adjuvant radiotherapy. In the intracranial location, this 
lesion may disrupt the critical areas of the brain, causing 
serious complications like visual problems, nerve 
palsies, and hemiparesis. Hence, an early diagnosis and 
management are key to manage time and effectively 
these patients.
IIMT can present in all age groups and has 
been almost equally reported in males and females. 
Headache is the most common presenting symptom, 
and the frontal lobe is the most common intracranial 
site. Dural attachment is noted in many cases. Mostly 
unifocal; however, multifocal lesions are also noted. 
In the study by M Kilinc et al.,3 multiple intracranial 
and spinal sites were involved. Multiple intracranial 
sites were also found to be involved in a study by M 
Guduk et al.4
The complete surgical excision of the lesion has 
been found to provide good results. In a study by M 
Guduk et al.,4 IIMT involving multiple intracranial sites 
was managed with complete excision of all the lesions, 
and no recurrence was reported.
Incomplete excision of the lesion, on the other 
hand, was found to be associated with recurrence 
and may require radiotherapy. In a case study by JJ 
Renfrow,36 relapsing and recurring lesions of IIMT 
were encountered. This study explored the erythrocyte 
sedimentation rate (ESR) as a tool for monitoring the 
recurrence of IIMT.
Some cases also showed a locally aggressive 
nature. In a study by A Fukunaga,6 an aggressive 
nature of the lesion was evidenced by its spread 
from extra to intracranial location. Osteal erosion 
was reported associated with IIMT in a study by AM 
Buccoliero et al.,23 while relapsing perichondritis was 
found in a study by K Sato.27
Special histological features have been brought 
out in cases of IIMT in the form of necrosis,10 extensive 
ossification,25 and multiloculated cystic changes.26
Although metastasis has not been reported, 
cases with initial involvement in an extracranial site 
(lung) have been reported. In a case reported by 
Greiner et al.19 the lesion involved the lung followed 
by the brain involvement four years later.
Polyclonal gammopathy was noted associated 
with intracranial PSGs in studies by SG West2 and D 
Figarella et al.,24 while association with EBV was noted 
in the study by A Fukunaga.6 The association with IGG4 
was found in 2 out of 4 cases by D Chen30 and in one 
case by Forcucci et al.37 ALK 1 was studied by D Chen30 
in four cases and was negative.
Although surgical excision, steroid therapy, and 
radiotherapy have been the mainstay of treatment of 
IIMTS, other modalities like mercaptopurine (6MP)40or 
Rituximab35 has also been tried in some cases.
CONCLUSION
IIMT is a rare pathological diagnosis. Timely 
management of cases of IIMTs is crucial to reduce 
morbidity. To rightly diagnose IIMTs, one needs to 
have a high index of suspicion as these cases are likely 
to be misdiagnosed as meningioma on neuroimaging. 
Complete surgical excision should be attempted while 
the lesion is small to prevent a recurrence. The addition 
of more cases to the literature, with their associated 
features, will help us in further improving the current 
understanding of IIMTs.
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